ALGN Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

1.03B

+3.68%

2.963

+21.43%

1.01B

+3.52%

2.420

+13.61%

1.05B

+4.03%

2.683

+7.77%

Estimates Revision

The market is revising Upward the revenue expectations for Align Technology, Inc. (ALGN) for FY2025, with the revenue forecasts being adjusted by 0.27% over the past three months. During the same period, the stock price has changed by 31.03%.

Revenue Estimates for FY2025

Revise Upward

+0.27%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+1%

In Past 3 Month

Stock Price

Go Up

+31.03%

In Past 3 Month

11 Analyst Rating

Wall Street analysts forecast ALGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALGN is 171.33 USD with a low forecast of 140.00 USD and a high forecast of 200.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

4 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

140.00

Averages

171.33

High

200.00

Current: 0.000

Low

140.00

Averages

171.33

High

200.00

Evercore ISI

Outperform

maintain

$170

2025-12-09

Reason

Evercore ISI

Price Target

$170

2025-12-09

maintain

Outperform

Reason

Evercore ISI says November website traffic data for Align Technology's key website suggests a range "broadly exceeding" Street expectations for Q4 case shipments of about 651,000. If web traffic in December remains in line with October and November and conversion rates hold steady, the data imply an estimated 668,000 cases for Q4, according to the analyst, who has an Outperform rating and $170 price target on Align shares.

Barclays

Hold

initiated

$170

2025-12-08

Reason

Barclays

Price Target

$170

2025-12-08

initiated

Hold

Reason

Barclays initiated coverage of Align Technology with an Equal Weight rating and $170 price target. The firm started the U.S healthcare technology and distribution industry with a neutral view. Barclays is most bullish on the drug distributors and has a more mixed view of the dental and healthcare information technology sub-sectors.

Stifel

Buy

maintain

$200

2025-12-05

Reason

Stifel

Price Target

$200

2025-12-05

maintain

Buy

Reason

Stifel reiterated a Buy rating and $200 price target on Align Technology, confirming that Angelalign will implement a price increase on January 1. The firm views the price increase as material to the stock, noting that while some specifics are a little unclear, it will take hold in the U.S., though it is less clear if it will be effective globally. An Angel price increase could further strengthen the case/appeal of Align's pending "zero refinement" plan, which Stifel believes will be priced at roughly $850, with that list price now likely lower than Angelalign, the analyst tells investors in a research note. With Angel's price now moving higher, the argument of Align Technology losing less share or winning back share should strengthen more, the analyst adds.

Evercore ISI

Outperform

maintain

$160 -> $170

2025-10-30

Reason

Evercore ISI

Price Target

$160 -> $170

2025-10-30

maintain

Outperform

Reason

Evercore ISI raised the firm's price target on Align Technology to $170 from $160 and keeps an Outperform rating on the shares after "a strong Q3 performance" with cases up 4.9% year-over-year, topping expectations. A 22c beat on EPS "underlines the effective cost management and operational leverage," the analyst tells investors.

Piper Sandler

Jason Bednar

Overweight

maintain

$190 -> $200

2025-10-30

Reason

Piper Sandler

Jason Bednar

Price Target

$190 -> $200

2025-10-30

maintain

Overweight

Reason

Piper Sandler analyst Jason Bednar raised the firm's price target on Align Technology to $200 from $190 and keeps an Overweight rating on the shares. Shares of Align have been out-of-favor with investors since the Q2 print, in part because of revenue visibility challenges the business had encountered, but also due to an implied Q4 revenue ramp that looked challenging based on historical seasonality, the firm notes. But Q3 cured both of those ills as management delivered broad volume upside in the period, which has the effect of also shortening the putt to hit the originally implied Q4 targets, adds Piper.

UBS

Neutral

downgrade

$160 -> $155

2025-10-16

Reason

UBS

Price Target

$160 -> $155

2025-10-16

downgrade

Neutral

Reason

UBS lowered the firm's price target on Align Technology to $155 from $160 and keeps a Neutral rating on the shares. Shares are down 38% year-to-date and 81% from 2021 highs, trading at a historically low multiple after a weak Q2, the analyst tells investors in a research note. Sentiment remains pressured by share losses to traditional braces and competitors, declining ASPs for Invisalign, soft consumer confidence, limited management visibility, and muted dental demand, factors that have eroded confidence in Align's ability to meet Q3 expectations or maintain full-year guidance, the firm says.

Valuation Metrics

The current forward P/E ratio for Align Technology Inc (ALGN.O) is 14.44, compared to its 5-year average forward P/E of 33.61. For a more detailed relative valuation and DCF analysis to assess Align Technology Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

33.61

Current PE

14.44

Overvalued PE

49.01

Undervalued PE

18.22

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

22.51

Current EV/EBITDA

9.59

Overvalued EV/EBITDA

32.77

Undervalued EV/EBITDA

12.26

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

6.26

Current PS

2.72

Overvalued PS

9.44

Undervalued PS

3.08

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ALGN News & Events

Events Timeline

No data

News

9.5

01-02Businesswire

Align Technology Sets Q4 2025 Earnings Release Date and Conference Call Schedule

2.0

2025-12-31NASDAQ.COM

Deckers Brands Stock Down 50% Yet Promising Outlook Ahead

4.0

2025-12-23NASDAQ.COM

S&P 500 Index Rises 0.23% as Economic Confidence Strengthens

People Also Watch

Frequently Asked Questions

What is Align Technology Inc (ALGN) stock price today?

The current price of ALGN is 172.79 USD — it has increased 1.3 % in the last trading day.

What is Align Technology Inc (ALGN)'s business?

Align Technology, Inc. is a global medical device company that designs, manufactures, and sells the Invisalign system of clear aligners, iTero intraoral scanners, and exocad computer-aided design and computer-aided manufacturing (CAD/CAM) software for digital orthodontics and restorative dentistry. The Company provides Align Digital Platform. Its segments include Clear Aligner, and Imaging Systems and CAD/CAM Services (Systems and Services). The Clear Aligner segment consists of comprehensive products, non-comprehensive products and non-case products. Its comprehensive products include Invisalign Comprehensive and Invisalign First. The Company's non-case products include retention products, Invisalign training and adjusting tools. It offers up to four sets of custom clear aligners called Vivera retainers. The Systems and Services segment consists of its iTero intraoral scanning systems. Its services include subscription software, disposables, rentals, leases and pay per scan services.

What is the price predicton of ALGN Stock?

What is Align Technology Inc (ALGN)'s revenue for the last quarter?

Align Technology Inc revenue for the last quarter amounts to 995.69M USD, increased 1.82 % YoY.

What is Align Technology Inc (ALGN)'s earnings per share (EPS) for the last quarter?

Align Technology Inc. EPS for the last quarter amounts to 0.78 USD, decreased -49.68 % YoY.

What changes have occurred in the market's expectations for Align Technology Inc (ALGN)'s fundamentals?

How many employees does Align Technology Inc (ALGN). have?

Align Technology Inc (ALGN) has 20945 emplpoyees as of January 10 2026.

What is Align Technology Inc (ALGN) market cap?

Today ALGN has the market capitalization of 12.40B USD.